Blood cancer patients' immune system may hold clues to severe COVID-19
NCT ID NCT07204366
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examines whether people with certain blood cancers (myeloproliferative neoplasms) have autoantibodies that block a key immune protein called type I interferon. These autoantibodies may increase the risk of severe COVID-19. Researchers will test blood samples from 219 participants to see how common these autoantibodies are and if they relate to COVID-19 outcomes. No treatment is given; the goal is to gather knowledge.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fondazione IRCCS Policlinico San Matteo
Pavia, Lombardy, 27100, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a hormone mimic curb the need for bloodletting in a blood cancer?
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a Dual-Action pill tame bone marrow tumors?